The Pulmonary Hypertension Association (PHA) is promoting several events throughout November — the Pulmonary Hypertension (PH) Awareness Month. This year, people are encouraged to discover the risk factors and symptoms of PH, and the challenges faced by those living with the disease, and their families. PH…

The combination of pulmonary endarterectomy (PEA), a surgery to remove blood clots in the lungs, and balloon pulmonary angioplasty (BPA), the use of balloons to open narrowed or blocked blood vessels — could improve outcomes for people with chronic thromboembolic pulmonary hypertension (CTEPH), researchers reported. Treatment, including…

For the first time, the long-term use of antipsychotic medications has been linked to the development of chronic thromboembolic pulmonary hypertension (CTEPH), a case study reports.  The authors recommend that CTEPH should be considered in patients who receive antipsychotics and also have symptoms associated…

Adults with chronic thromboembolic pulmonary hypertension (CTEPH) experience more breathing stoppages during sleep (apnea), lower blood oxygen, and higher levels of pro-inflammatory proteins in the blood than people with idiopathic pulmonary arterial hypertension who…

Robot-assisted pulmonary artery denervation (PADN) — a minimally invasive surgical procedure that destroys some of the nerves innervating the pulmonary artery to reduce blood pressure — can lower heart strain and improve exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH). That finding was reported in…

Bayer has opened its second annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a grant funding program to support clinical research projects into pulmonary hypertension (PH), particularly those focused on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The program, one of…

Among people with chronic thromboembolic pulmonary hypertension (CTEPH), certain anticoagulants may reduce the risk of serious bleeding more than others, a new study shows. The study, “Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational…

Levels of a circular RNA molecule in the blood could help diagnose and predict the clinical outcomes of those with idiopathic pulmonary arterial hypertension (IPAH), a study suggests. The study, “Elevated serum circ_0068481 levels as a potential diagnostic and prognostic indicator in idiopathic pulmonary arterial hypertension,”…

Actelion Pharmaceuticals has withdrawn all ongoing worldwide requests for expanded approval of Opsumit (macitentan), a pulmonary arterial hypertension (PAH) medicine, to treat adults with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). The decision was not driven by any safety concerns, Actelion, one of …

Higher levels of a protein involved in certain immune responses, called soluble suppression of tumorigenicity-2 (sST2), are associated with more severe pulmonary hypertension (PH) and heart dysfunction, a study found. This protein’s potential use as a prognostic biomarker for PH, however, seems to be limited. The study, “The Prognostic Value of…

Analysis of a North American pediatric registry revealed significant variability of pulmonary hypertension (PH) subtypes among children of different racial and ethnic groups, with reduced survival rates among black children with lung disease-associated PH, a new study reports. The study, “Racial…

The heart transplant program at the University of California San Diego Health has achieved the best one-year patient survival rate in the U.S., with surgeons working at the Cardiovascular Institute performing more than 50 heart transplants each year, data from the Scientific Registry of Transplant Recipients…